This analysis was performed across the control, AD, AD+LBD, and LBD groups, excluding the PSP and CBD groups, to reduce the influence of tau pathology other than that associated with AD and to assess the impact of each background pathology on the Comparison Scores. The gene discussed is MAPT; the disease is red-green color blindness.